Rice Hall James & Associates LLC acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,896 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,316,000.

Several other large investors also recently modified their holdings of JAZZ. Somerset Trust Co raised its stake in shares of Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock worth $497,000 after buying an additional 14 shares during the last quarter. Level Four Advisory Services LLC raised its stake in shares of Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock worth $389,000 after buying an additional 23 shares during the last quarter. World Asset Management Inc raised its stake in shares of Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after buying an additional 27 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in shares of Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock worth $951,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 87.22% of the company’s stock.

Jazz Pharmaceuticals PLC (JAZZ) opened at 143.97 on Tuesday. The company has a market cap of $8.65 billion, a P/E ratio of 22.18 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The stock has a 50 day moving average of $154.48 and a 200-day moving average of $147.25.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. The firm had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.67 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $10.87 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Rice Hall James & Associates LLC Acquires Shares of 14,896 Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/rice-hall-james-associates-llc-acquires-shares-of-14896-jazz-pharmaceuticals-plc-nasdaqjazz/1489489.html.

A number of equities research analysts recently commented on the stock. Leerink Swann set a $179.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Thursday, April 27th. Sanford C. Bernstein set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “market perform” rating in a report on Monday, May 22nd. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective on the stock in a report on Tuesday, June 6th. Deutsche Bank AG restated a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $182.72.

In other news, Director Rick E. Winningham sold 5,000 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $150.00, for a total value of $750,000.00. Following the completion of the sale, the director now owns 10,391 shares in the company, valued at $1,558,650. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $150.65, for a total transaction of $30,130.00. Following the completion of the sale, the executive vice president now owns 22,223 shares of the company’s stock, valued at approximately $3,347,894.95. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,062 shares of company stock valued at $1,705,373. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.